AC Immune SA
ACIU
$1.67
$0.010.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -14.95% | -95.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.95% | -95.61% | |||
| Cost of Revenue | -1.50% | 7.35% | |||
| Gross Profit | 0.46% | -231.12% | |||
| SG&A Expenses | 8.94% | 4.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 106.92% | 27.73% | |||
| Total Operating Expenses | 0.68% | 6.81% | |||
| Operating Income | -1.63% | -352.27% | |||
| Income Before Tax | -17.69% | -382.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.67% | -382.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.67% | -382.73% | |||
| EBIT | -1.63% | -352.27% | |||
| EBITDA | -1.70% | -335.76% | |||
| EPS Basic | -17.18% | -382.42% | |||
| Normalized Basic EPS | -17.26% | -382.41% | |||
| EPS Diluted | -15.25% | -416.44% | |||
| Normalized Diluted EPS | -17.26% | -385.28% | |||
| Average Basic Shares Outstanding | 0.42% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.42% | -0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||